Jue Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jue Hou has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Aimee L. Edinger
Department of Developmental and Cell Biology, University of California Irvine, Irvine, CA, 92697, USA.
1 shared publication Alison N. McCracken
Department of Developmental and Cell Biology, University of California Irvine (UCI), Irvine, California, USA
1 shared publication- Archna Ravi
Department of Developmental and Cell Biology, University of California Irvine (UCI), Irvine, California, USA
1 shared publication Atsuo T. Sasaki
Departments of Internal Medicine, Neurosurgery, and Cancer Biology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
1 shared publication- Bin Chen
Department of Chemistry, Université de Montréal, Montreal, Quebec, Canada
1 shared publication Brendan T. Finicle
Department of Developmental and Cell Biology, University of California Irvine (UCI), Irvine, California, USA
1 shared publication
Latest Publications
- Open Access
- 26 September 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (11) , 4088-4102
Targeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways
Oncogenic mutations drive anabolic metabolism, creating a dependency on nutrient influx through transporters, receptors, and macropinocytosis. While sphingolipids suppress tumor growth by downregulating nutrient transporters, macropinocytosis and autophagy still provide cancer cells with fuel. Therapeutics that simultaneously disrupt these parallel nutrient access pathways have potential as powerful starvation agents. Here, we describe a water-soluble, orally bioavailable synthetic sphingolipid, SH-BC-893, that triggers nutrient transporter internalization and also blocks lysosome-dependent nutrient generation pathways. SH-BC-893 activated protein phosphatase 2A (PP2A), leading to mislocalization of the lipid kinase PIKfyve. The concomitant mislocalization of the PIKfyve product PI(3,5)P2 triggered cytosolic vacuolation and blocked lysosomal fusion reactions essential for LDL, autophagosome, and macropinosome degradation. By simultaneously limiting access to both extracellular and intracellular nutrients, SH-BC-893 selectively killed cells expressing an activated form of the anabolic oncogene Ras in vitro and in vivo. However, slower-growing, autochthonous PTEN-deficient prostate tumors that did not exhibit a classic Warburg phenotype were equally sensitive. Remarkably, normal proliferative tissues were unaffected by doses of SH-BC-893 that profoundly inhibited tumor growth. These studies demonstrate that simultaneously blocking parallel nutrient access pathways with sphingolipid-based drugs is broadly effective and cancer selective, suggesting a potential strategy for overcoming the resistance conferred by tumor heterogeneity.
- 26 September 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (11) , 4088-4102
Open AccessTargeting cancer metabolism by simultaneously disrupting parallel nutrient access pathways
Oncogenic mutations drive anabolic metabolism, creating a dependency on nutrient influx through transporters, receptors, and macropinocytosis. While sphingolipids suppress tumor growth by downregulating nutrient transporters, macropinocytosis and autophagy still provide cancer cells with fuel. Therapeutics that simultaneously disrupt these parallel nutrient access pathways have potential as powerful starvation agents. Here, we describe a water-soluble, orally bioavailable synthetic sphingolipid, SH-BC-893, that triggers nutrient transporter internalization and also blocks lysosome-dependent nutrient generation pathways. SH-BC-893 activated protein phosphatase 2A (PP2A), leading to mislocalization of the lipid kinase PIKfyve. The concomitant mislocalization of the PIKfyve product PI(3,5)P2 triggered cytosolic vacuolation and blocked lysosomal fusion reactions essential for LDL, autophagosome, and macropinosome degradation. By simultaneously limiting access to both extracellular and intracellular nutrients, SH-BC-893 selectively killed cells expressing an activated form of the anabolic oncogene Ras in vitro and in vivo. However, slower-growing, autochthonous PTEN-deficient prostate tumors that did not exhibit a classic Warburg phenotype were equally sensitive. Remarkably, normal proliferative tissues were unaffected by doses of SH-BC-893 that profoundly inhibited tumor growth. These studies demonstrate that simultaneously blocking parallel nutrient access pathways with sphingolipid-based drugs is broadly effective and cancer selective, suggesting a potential strategy for overcoming the resistance conferred by tumor heterogeneity.